Linagliptin Rowex

Linagliptin, the active ingredient in Linagliptin Rowex, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to improve glycaemic control when used with diet and exercise.

GNH USA supplies Linagliptin Rowex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin Rowex belongs to the DPP‑4 inhibitor class and is used to treat disorders of glucose metabolism.

- Type 2 diabetes mellitus (monotherapy): provides glycaemic reduction without causing weight gain. - Type 2 diabetes mellitus (combination with metformin): enhances overall glucose‑lowering effect. - Type 2 diabetes mellitus (adjunct to lifestyle modification): assists patients in reaching HbA1c targets when diet and exercise alone are insufficient.

Linagliptin is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection. - Headache: transient and usually mild. - Dizziness: occasional light‑headedness. - Gastrointestinal discomfort: includes nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: such as angioedema or anaphylaxis. - Bullous pemphigoid: rare skin blistering disorder. - Stevens‑Johnson syndrome: life‑threatening mucocutaneous reaction. - Hepatic injury: elevated liver enzymes or hepatitis.

When prescribing Linagliptin Rowex, clinicians should consider several safety aspects.

- Renal impairment: evaluate renal function and adjust therapy if needed. - Hepatic disease: monitor liver enzymes during treatment. - Cardiovascular risk: use cautiously in patients with heart failure. - Pregnancy and lactation: avoid unless potential benefit justifies the risk. - Drug interactions: review concomitant medications for possible interactions. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Linagliptin may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase linagliptin exposure and risk of toxicity. - Concurrent insulin secretagogues: heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and renal function. - Antihypertensive agents: observe blood pressure for additive effects. - Other DPP‑4 inhibitors: avoid duplication of mechanism.